Denali Therapeutics stock (US24823R1077): Takeda exits DNL593 partnership

Denali Therapeutics regains full rights to DNL593 after Takeda's exit from the dementia drug deal, with Phase 1/2 data expected by late 2026.

Denali Therapeutics Inc. recently regained full rights to its investigational ALS and dementia drug DNL593 following Takeda's decision to exit the partnership. The move allows Denali to advance the asset independently, targeting a Phase 1/2 data readout by late 2026, according to Benzinga as of May 2026. This development comes amid Denali's presentations at major healthcare conferences.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Denali Therapeutics Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Neurology, rare diseases
• Key revenue drivers: Pipeline advancements, partnerships
• Home exchange/listing venue: Nasdaq (DNLI)
• Trading currency: USD

Denali Therapeutics: core business model

Denali Therapeutics focuses on developing therapies for neurodegenerative and lysosomal storage diseases using its Transport Vehicle (TV) technology to cross the blood-brain barrier. The platform enables delivery of biologic drugs to the brain, targeting conditions like Alzheimer's, Parkinson's, and ALS. The company, founded in 2015 and headquartered in South San Francisco, California, remains in the clinical-stage phase with no approved products as of its latest updates.

Denali's pipeline includes candidates like DNL343 for ALS and DNL788 for multiple sclerosis, both leveraging the TV platform. Strategic partnerships have been central to its model, providing funding and expertise, though recent shifts like the Takeda exit highlight evolving collaborations. For US investors, Denali offers exposure to innovative biotech targeting high-unmet needs in neurology.

Main revenue and product drivers for Denali Therapeutics

Denali generates revenue primarily through collaboration agreements, milestone payments, and research funding rather than product sales. Key drivers include progress in its ATV platform for antibody transport and ETV for enzymes, with potential milestones from partners like Takeda prior to the recent termination. The DNL593 program, now fully controlled by Denali, represents a significant near-term catalyst with planned data readouts.

Pipeline advancements drive investor interest, particularly in neurodegenerative diseases affecting the aging US population. Denali presented updates at the Bank of America Global Healthcare Conference, discussing operational progress with Chief Operating Officer Alex Schuth, as noted in GuruFocus as of May 2026.

Industry trends and competitive position

The neurodegenerative disease sector is booming, with US market projections for Alzheimer's therapies alone exceeding $10 billion by 2030 per sector reports. Competitors like Biogen and Eli Lilly have approved drugs, but Denali differentiates via its TV technology for superior brain penetration. Takeda's exit from DNL593, linked to a prior Denali dementia partnership, underscores risks in alliances but also opportunities for full control.

Why Denali Therapeutics matters for US investors

Listed on Nasdaq, Denali provides US investors direct access to cutting-edge brain delivery tech amid rising demand for dementia and ALS treatments. With regulatory submissions planned for partners' assets in the US and a robust pipeline, it aligns with biotech trends fueled by the US healthcare economy.

Conclusion

The Takeda exit from the DNL593 partnership positions Denali Therapeutics to fully control a promising asset with data expected in late 2026. Combined with conference updates and pipeline momentum, this refocuses the company on independent advancement. Investors will watch clinical progress closely amid biotech volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.